摘要
目的:评价多西他赛单药联合比卡鲁胺治疗中晚期前列腺癌临床疗效及安全性。方法:选取2009年6月1日-2010年6月1日笔者所在医院收治的40例前列腺癌患者的临床资料进行回顾性分析,视情况予比卡鲁胺结合多西他赛治疗,观察其疗效及安全性。结果:40例患者治疗期内随访3～48个月,有效22例,疼痛缓解8例,进展10例。40例治疗后,开始PSA均有下降,随访第1年,28例血PSA降至正常,第2年,20例病情稳定,6例下降不满意或出现反跳,改用其他治疗方式。到2012年12月为止,20例存活,其余12例死于前列腺癌进展,8例死于其他疾病。本组治疗期间出现潮热感10例,男子乳房触痛5例,乳房发育2例,胃肠道不良反应(恶心、呕吐)2例,骨髓抑制2例,无不良反应19例。结论:多西他赛联合比卡鲁胺治疗中晚期前列腺癌疗效显著,值得推广。
[ Abstract ] Objective： To evaluate docetaxel combination bicalutamide monotherapy treatment of advanced prostate cancer clinical efficacy and safety. Method： Selection on June 1, 2009 to June 1, 2010, the author＇s hospital treated the clinical data of 40 patients with prostate cancer were retrospectively analyzed, as the case to the more than carew amine combining west he treatment, observe its efficacy and safety.Result： Treatment period, 40 patients were followed up for 3 - 48 months, 22 cases, 8 cases there was pain relief and progress in 10 cases.40 patients after treatment, began to PSA are falling, followed up for 1 year, 28 eases dropped to normal blood PSA, 2 years, 20 cases in stable condition, 6 cases fell dissatisfied or bounce, to switch to other treatments. Until December 2012, 20 cases survived, the remaining 12 cases died of prostate cancer progression, 8 eases died of other diseases.Hot flashes are shown during treatment of 10 cases, male breast tenderness in 5 eases, 2 cases of breast development, gastrointestinal adverse reactions （nausea, vomiting） in 2 cases, bone marrow suppression in 2 cases, 19 eases without adverse reaction.Conclusion： Doeetaxel combined bicalutamide treatment of advanced prostate cancer, a significant effect, worthy of promotion.
出处
《中外医学研究》
2014年第3期124-125,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
前列腺癌
多西他赛
内分泌
比卡鲁胺
Prostate cancer
Docetaxel
Endocrine therapy
Bicalutamide
